{"id":9294,"date":"2023-05-16T04:53:26","date_gmt":"2023-05-16T08:53:26","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/uniqure-to-sell-royalty-interest-in-hemgenix-for-up-to-400-million\/"},"modified":"2023-05-16T04:53:26","modified_gmt":"2023-05-16T08:53:26","slug":"uniqure-to-sell-royalty-interest-in-hemgenix-for-up-to-400-million","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=9294","title":{"rendered":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million"},"content":{"rendered":"
\n

By Chris Wack<\/p>\n

<\/pre>\n
uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of its Hemgenix-branded etranacogene dezaparvovec drug to treat hemophilia B, to HealthCare Royalty and Sagard Healthcare for up to $400 million in cash.<\/p>\n
\n
Under the terms of the agreement, the biopharmaceutical investment firms will pay uniQure $375 million in cash upfront in exchange for the lowest royalty tier of CSL Behring’s worldwide sales of Hemgenix up to 1.85 times the purchase price until June 30, 2032, or up to 2.25 times the purchase price from June 31, 2032 through Dec. 31, 2038.<\/p>\n
The Massachusetts and Netherlands-based gene therapy company also is eligible to receive an additional $25 million milestone payment from HealthCare Royalty and Sagard Healthcare if 2024 sales of Hemgenix exceed a pre-specified threshold.<\/p>\n
uniQure expects to extend its cash runway into the second quarter of 2026 with the transaction and to retain the rights to all other royalties and contractual milestones under its existing commercialization and license agreement with CSL Behring totaling up to $1.5 billion.<\/p>\n
<\/pre>\n
Write to Chris Wack at chris.wack@wsj.com<\/p>\n
<\/pre>\n<\/p><\/div>\n<\/div>\n
Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of its Hemgenix-branded etranacogene dezaparvovec drug to treat hemophilia B, to HealthCare Royalty and Sagard Healthcare for up to $400 million in cash. Under the terms of the agreement, the […]<\/p>\n","protected":false},"author":1,"featured_media":1898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-9294","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nuniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=9294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=9294\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-16T08:53:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9294#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9294\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million\",\"datePublished\":\"2023-05-16T08:53:26+00:00\",\"dateModified\":\"2023-05-16T08:53:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9294\"},\"wordCount\":195,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=9294#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9294\",\"url\":\"https:\/\/ifintechworld.com\/?p=9294\",\"name\":\"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-05-16T08:53:26+00:00\",\"dateModified\":\"2023-05-16T08:53:26+00:00\",\"description\":\"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=9294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=9294\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=9294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld","description":"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=9294","og_locale":"en_US","og_type":"article","og_title":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld","og_description":"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of","og_url":"https:\/\/ifintechworld.com\/?p=9294","og_site_name":"iFintechWorld","article_published_time":"2023-05-16T08:53:26+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=9294#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=9294"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million","datePublished":"2023-05-16T08:53:26+00:00","dateModified":"2023-05-16T08:53:26+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=9294"},"wordCount":195,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=9294#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=9294","url":"https:\/\/ifintechworld.com\/?p=9294","name":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-05-16T08:53:26+00:00","dateModified":"2023-05-16T08:53:26+00:00","description":"By Chris Wack uniQure said Monday it is selling a portion of its royalty rights, due from rare disease biopharmaceutical company CSL Behring, for sales of","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=9294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=9294"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=9294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"uniQure to Sell Royalty Interest in Hemgenix for Up To $400 Million"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9294"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9294\/revisions"}],"predecessor-version":[{"id":9295,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/9294\/revisions\/9295"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1898"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}